Can a higher relaxivity contrast agent hinder subendocardial infarct detection in viability imaging?
- PDF / 403,803 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 10 Downloads / 148 Views
BioMed Central
Open Access
Can a higher relaxivity contrast agent hinder subendocardial infarct detection in viability imaging? June Yamrozik*, Vikas K Rathi, Ronald B Williams, Janice Meister, Geetha Rayarao, Diane A Vido, Mark Doyle and Robert WW Biederman Address: The Center for Cardiovascular Magnetic Resonance Imaging, The Gerald McGinnis Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA, USA * Corresponding author
from 13th Annual SCMR Scientific Sessions Phoenix, AZ, USA. 21-24 January 2010 Published: 21 January 2010 Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):T11
doi:10.1186/1532-429X-12-S1-T11
Abstracts of the 13th Annual SCMR Scientific Sessions - 2010
Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/files/pdf/1532-429X-12-S1-infoThis abstract is available from: http://jcmr-online.com/content/12/S1/T11 © 2010 Yamrozik et al; licensee BioMed Central Ltd.
Introduction Recently, higher relaxivity contrasts agents have been advocated for use in infarct imaging. Specifically, MultiHance® (gadobenate dimeglumine) has higher relaxivities (r1 and r2, 9.71 and 12.51) compared to standard Magnevist (gadopentetate dimeglumine) (r1 and r2, 4.91 and 6.31). Will this higher relaxivity show better visualization of subendocardial infarcts or hinder the visualization?
Purpose We hypothesize that a 0.15 mmol/kg dosage of MultiHance® with its higher relaxivity will produce higher signal intensity in the blood pool cavity compatible with the signal of a subendocardial infarct as compared to a standard 0.20 mmol/kg dosage of Magnevist.
Methods A total of 42 patients with GFR >60mL/min/1.73 m2 were imaged. Twenty-one (21) patients (17M, 4F), with postmyocardial infarction underwent a standard viability cardiac MRI (CMR) utilizing a total of 0.2mmol/kg gadolinium dosage (Magnevist-Berlex, New Jersey, USA). Twentyone (21) patients (14M, 7F), with post-myocardial infarction underwent a standard viability cardiac MRI (CMR) utilizing a total of 0.15mmol/kg MultiHance® dosage (Bracco Diagnostics, Princeton, N J, USA). The scans were acquired on a GE CV/i Excite Version 12, 1.5 T system (GE, Milwaukee, WI). The sequence utilized for optimum visualization of the blood pool cavity, nulled myocardium and infarct was a standard 2D Gradient Echo IRP (FGR
with inversion recovery prep) and was performed at 10 and 20 min post -contrast administration. The signal intensity (SI) of infarct to left ventricular (LV) blood pool cavity was measured in all 42 patients as well as infarct size.
Results All patients successfully completed the CMR examination without any difficulty. The signal intensity (SI) of the blood pool cavity, infarct and the ratio between the two was measured at 10 and 20 minute post-contrast. (Table 1) T-Tests were performed on the ratio between the MultiHance® and Magnevist at 10 (p=ns)and 20 (p
Data Loading...
